Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML

This publication has 31 references indexed in Scilit:

• Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia
  Blood, 2006
• High Stem Cell Frequency in Acute Myeloid Leukemia at Diagnosis Predicts High Minimal Residual Disease and Poor Survival
  Clinical Cancer Research, 2005
• Minimal Residual Disease in Acute Myeloid Leukemia Is Predicted by an Apoptosis-Resistant Protein Profile at Diagnosis
  Clinical Cancer Research, 2005
• Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia
  Blood, 2004
• MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia
  Leukemia, 2004
• Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis
  Leukemia, 2003
• Acute Myeloid Leukemia and Acute Promyelocytic Leukemia
  Hematology-American Society Hematology Education Program, 2003
• The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
  Blood, 2001
• Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia
  Blood, 2000
• Immunophenotyping Investigation of Minimal Residual Disease Is a Useful Approach for Predicting Relapse in Acute Myeloid Leukemia Patients
  Blood, 1997